The National Cancer Institute (NCI) seeks parties to license software for modeling the targeted delivery of anti-cancer agents in solid tumors.
The software models the permeability and concentration of intravenously administered antibody anti-cancer agent conjugates in solid tumors. The models can be used to determine optimal dosing regimen of a therapeutic in a particular cancer type. Thirty factors that affect delivery rates and efficiencies are analyzed as variables in generating the models.
- Drug design
- Combination therapy
- Personalized medicine
- Accurate permeability modeling of anti-cancer therapeutics.
R.K. Jain et al. Delivery of molecular and cellular medicine to solid tumors. [PMID 11259838]
G.M. Thurber et al. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. [PMID 18541331]
Y. Pak et al. Antigen shedding may improve efficiencies for delivery of antibody-based anticancer agents in solid tumors. [PMID: 22562466]
K.C. Chen et al. Modeling recombinant immunotoxin efficacies in solid tumors. [PMID: 18183487]
- Research Material: NIH will not pursue patent prosecution for this technology